Results 301 to 310 of about 3,722,377 (405)
Pro‐ATO/Allicin Liposomes for Dual‐Pathway Targeting of p53‐Mutant Tumors
Schematic illustration of the “pro‐ATO”/allicin liposomal strategy. Liposomal encapsulation improves the stability and bioavailability of both agents while masking allicin's odor. Upon release in the tumor microenvironment, ATO reactivates structural p53 mutants, and allicin inhibits ATR signaling while releasing H2S, collectively inducing synthetic ...
Xiaoling Xu +11 more
wiley +1 more source
Successful thrombectomy for inferior vena cava thrombosis associated with an ovarian tumor: a case report. [PDF]
Mori K +7 more
europepmc +1 more source
Trojan Horse Strategy: How Biomimetic Nanomedicine Remodels the Tumor Microenvironment
This review focuses on biomimetic nanomedicines for tumor microenvironment (TME) remodeling, covering their diverse biomimetic types, design principles, and mechanisms of immune cell reprogramming and reversal of immunosuppressive microenvironments, with particular emphasis on their application in synergistic immunotherapy.
Wanrong Wang +7 more
wiley +1 more source
Mucinous Ovarian Adenocarcinoma cloaked as an intestinal Tumor-Case Report
Mazzini LR +5 more
openalex +1 more source
HEK‐293T‐derived CD3ε Nb‐engineered EVs to generate dual‐targeting CAR‐T cells directly in vivo. These EVs selectively deliver CAR.BiTE transgenes into T cells and reprogramed to HLA‐G/PD‐L1‐targeting effector cells with enhanced memory and persistence.
Shi‐Wei Huang +27 more
wiley +1 more source
A novel strategy for in situ multiplexed miRNA analysis of plasma extracellular vesicles (EValarm) has been developed. EValarm enables straightforward detection of different extracellular vesicle miRNAs from plasma samples through systematic screening of liposome surface charges, without requiring complex pretreatment steps, and achieves satisfactory ...
Jing‐Yuan Ma +13 more
wiley +1 more source
Random forest-based model for the recurrence prediction of borderline ovarian tumor: clinical development and validation. [PDF]
Yan L +8 more
europepmc +1 more source

